UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

Chinese medical journal, 2019-10, Vol.132 (19), p.2315-2324

2019

Volltextzugriff (PDF)

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Journal of hepatology, 2011-11, Vol.55 (5), p.1121-1131

2011

Volltextzugriff (PDF)

Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: The lower, the better

Journal of gastroenterology and hepatology, 2010-12, Vol.25 (12), p.1812-1814

2010

Volltextzugriff (PDF)

Current Challenges and the Management of Chronic Hepatitis C in Mainland China

Journal of clinical gastroenterology, 2014-09, Vol.48 (8), p.679-686

2014

Volltextzugriff (PDF)

Antiviral therapy for various stages of HBV-related diseases: Lamivudine and beyond

Journal of gastroenterology and hepatology, 2008-05, Vol.23 (5), p.681-682

Jia, Ji-Dong

2008

Volltextzugriff (PDF)

Impact of reimbursement program on liver‐related mortality in patients with chronic hepatitis B in Beijing, China

Journal of digestive diseases, 2019-09, Vol.20 (9), p.467-475

2019

Volltextzugriff (PDF)

Antiviral therapy for hepatitis B in special populations

Antiviral therapy, 2010-01, Vol.15 (8), p.1067-1075

2010

Volltextzugriff (PDF)

Progress in diagnosis and treatment of liver cirrhosis

Zhonghua gan zang bing za zhi, 2009-04, Vol.17 (4), p.241

2009

Volltextzugriff (PDF)

The overview of the seminar on chronic hepatitis B

Zhonghua gan zang bing za zhi, 2004-11, Vol.12 (11), p.698

2004

Volltextzugriff (PDF)

Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients

Zhonghua gan zang bing za zhi, 2009-12, Vol.17 (12), p.881

2009

Volltextzugriff (PDF)

Management of HBeAg negative chronic hepatitis B

Zhonghua gan zang bing za zhi, 2005-07, Vol.13 (7), p.539

Jia, Ji-dong

2005

Volltextzugriff (PDF)

Interferons for treating chronic hepatitis B

Zhonghua gan zang bing za zhi, 2007-11, Vol.15 (11), p.849

2007

Volltextzugriff (PDF)

Therapeutic strategies for chronic hepatitis B recommended by the American Association for the Study of Liver Diseases

Zhonghua gan zang bing za zhi, 2004-10, Vol.12 (10), p.623

2004

Volltextzugriff (PDF)

Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48

Zhonghua shi yan he lin chuang bing du xue za ji, 2007-06, Vol.21 (2), p.102

2007

Volltextzugriff (PDF)

The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52

Zhonghua gan zang bing za zhi, 2007-05, Vol.15 (5), p.342

2007

Volltextzugriff (PDF)

Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a

Zhonghua gan zang bing za zhi, 2007-07, Vol.15 (7), p.481

2007

Volltextzugriff (PDF)

A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B

Zhonghua gan zang bing za zhi, 2004-10, Vol.12 (10), p.589

2004

Volltextzugriff (PDF)

The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients

Zhonghua gan zang bing za zhi, 2006-08, Vol.14 (8), p.565

2006

Volltextzugriff (PDF)

Management of hepatitis C virus infection in the Asia-Pacific region: an update

The lancet. Gastroenterology & hepatology, 2017-01, Vol.2 (1), p.52-62

2017

Volltextzugriff (PDF)

Prevention and treatment of hepatitis B virus reinfection after liver transplantation

Chung-hua wai kʿo tsa chih, 2005-08, Vol.43 (15), p.976-979

2005

Volltextzugriff (PDF)

Retreatment with interferon of relapsed chronic hepatitis C patients

Zhonghua gan zang bing za zhi, 2006-01, Vol.14 (1), p.3

2006

Volltextzugriff (PDF)

The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C

Zhonghua gan zang bing za zhi, 2004-02, Vol.12 (2), p.72

2004

Volltextzugriff (PDF)

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B

Journal of hepatology, 2022-12, Vol.77 (6), p.1515-1524

2022

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

PublikationsformDissertationen

ThemaAntiviral Agents - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(9)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(23)

Sprache

Chinesisch
(14)
Englisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Hepatitis B, Chronic - Drug Therapy
(12)
Male
(10)
Adult
(9)
Female
(9)
Life Sciences & Biomedicine
(9)
Middle Aged
(9)
Science & Technology
(9)
Interferon-Alpha - Therapeutic Use
(8)
Gastroenterology & Hepatology
(7)
Lamivudine - Therapeutic Use
(7)
Adolescent
(6)
Treatment Outcome
(6)
Dna, Viral - Blood
(5)
Hepatitis B, Chronic - Virology
(5)
Recombinant Proteins
(5)
Young Adult
(5)
Genotype
(4)
Hepatitis B E Antigens - Blood
(4)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: The lower, the better

Current Challenges and the Management of Chronic Hepatitis C in Mainland China

Antiviral therapy for various stages of HBV-related diseases: Lamivudine and beyond

Impact of reimbursement program on liver‐related mortality in patients with chronic hepatitis B in Beijing, China

Antiviral therapy for hepatitis B in special populations

Progress in diagnosis and treatment of liver cirrhosis

The overview of the seminar on chronic hepatitis B

Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients

Management of HBeAg negative chronic hepatitis B

Interferons for treating chronic hepatitis B

Therapeutic strategies for chronic hepatitis B recommended by the American Association for the Study of Liver Diseases

Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48

The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52

Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a

A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B

The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients

Management of hepatitis C virus infection in the Asia-Pacific region: an update

Prevention and treatment of hepatitis B virus reinfection after liver transplantation

Retreatment with interferon of relapsed chronic hepatitis C patients

The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B

Aktive Filter

Suchergebnisse filtern